I think @jamit05 explained very well your acquisition cost of demerged Pharma shares. However, not sure if you can consider your actual acquisition cost of entire Piramal as the acquisition cost of Finance business…maybe you need to carve out the acquisition cost of Finance business in same ratio as demerger? Because if you consider the entire remainder as a base for loss calculation for finance business then in essence the Pharma shares should be considered free or 0 cost…
@jamit05 and others – how would the acquisition cost of Finance business work in this case to compute capital gain/loss? Would be good to know your thoughts
| Subscribe To Our Free Newsletter |
